Fractional Tumor Burden Mapping Enhances GBM Trial

Imaging Biometrics Limited

(“IB” or the “Company”)

Imaging Biometrics’ Fractional Tumor Burden Mapping Enhances GBM Trial

A glioblastoma (GBM) clinical trial led by Dr. Danielle Bazer, DO, neuro-oncologist and Lead for Neuro-Oncology at MD Anderson Cancer Center at Cooper University, is leveraging IB‘s Functional Tumor Burden (FTB) mapping to assess early treatment response and support key study endpoints. Funding for the FTB mapping component was made possible in part by the Musella Foundation for Brain Tumor Research & Information, Inc., whose support continues to accelerate innovation in brain tumor research.

This phase 2 feasibility study explores a novel treatment paradigm for patients with newly diagnosed high grade gliomas: administering temozolomide chemotherapy prior to radiation therapy. This innovative approach aims to determine whether early objective response rates-measured before radiation-can serve as reliable surrogates for drug activity. If validated, this paradigm could revolutionize early-phase clinical trial design in neuro-oncology, enabling more efficient drug screening and personalized treatment strategies.

IB’s FTB maps will provide voxel-level classification of tumor tissue based on perfusion characteristics, distinguishing active tumor from necrosis and treatment-related changes – a critical distinction that conventional imaging often fails to make. By comparing baseline and post-treatment FTB maps, deeper insights will be gained into tumor response trajectories and the biological impact of early chemotherapy-particularly in MGMT methylated tumors, which are known to respond more favorably to temozolomide.

“FTB mapping gives us a dynamic view of tumor behavior, which will help provide confirmation of response to drug therapy” said Dr. Bazer.

“We’re proud to support this trial with our imaging platform and grateful for the financial support from the Musella Foundation,” said Michael Schmainda, CEO of Imaging Biometrics. “FTB mapping is designed to bring clarity to brain tumor imaging, and we’re excited to see it making a difference.”

–ENDS–

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

About Imaging Biometrics® LLC:  IB is a wholly owned subsidiary of Imaging Biometrics Limited, (LON: IBAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company’s website at www.imagingbiometrics.com. Follow IB on X, @ImgBiometrics.